Levosimendan Stada (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that lowers both preload and afterload, thereby supporting overall cardiac performance.

The dosing regimen for Levosimendan Stada is determined by the prescribing physician based on the patient’s clinical condition, weight, and response to therapy. Healthcare professionals adjust the infusion rate and duration to achieve the desired hemodynamic effect while monitoring safety parameters.

Levosimendan Stada should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. The safety profile in these populations is not well established, so clinicians must evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan enhances contractility by sensitizing troponin C to existing calcium and adds vasodilatory effects through potassium‑channel activation. This dual action can provide hemodynamic support with a lower risk of calcium‑mediated arrhythmias compared with agents such as dobutamine or milrinone.

Levosimendan Stada should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until ready for preparation and use, and follow aseptic techniques during reconstitution.

Levosimendan Stada is administered intravenously, typically as an initial loading infusion followed by a continuous maintenance infusion. The exact infusion rate and duration are set by the treating physician, who monitors blood pressure, heart rate, and cardiac output throughout the therapy.

The most serious risks include severe hypotension, arrhythmias such as ventricular tachycardia, and myocardial ischemia. Patients should be closely monitored for blood pressure drops, abnormal heart rhythms, and signs of chest pain, especially during the loading phase of the infusion.

Levosimendan Stada is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals receiving concurrent potent vasodilators that could precipitate dangerous blood pressure falls. Caution is also advised in severe hepatic or renal impairment.